Our research focuses on targeting steroid metabolism to identify new therapeutic avenues for breast, prostate, ovarian, and colorectal cancer. With a strong interest in the enzymes (steroid sulphatase, sulphotransferases, 17b-hydroxysteroid dehydrogenases) involved in oestrogen activation, our work has identified numerous compounds that target these pathways and are efficacious in pre-clinical cancer models.
The group works using various cut-edge in vitro and in vivo methodologies to investigate the importance of steriodogenesis in endocrine-cancers. Collaborating with many groups both nationally and internationally, we are at the forefront of research on various enzymes, primarily steroid sulphatase and 17 b -hydroxysteroid dehydrogenases, essential to oestrogen and androgen activation and metabolism. We have recently developed novel LC/-MS-MS methods to accurately determine oestrogen metabolism and sulphation. This method will be vital to furthering our understanding of how certain tissue and cancer metabolise oestrogens, and how this is involved in proliferation and apoptosis. Furthermore, we have developed novel cell lines of various malignancies that stably over-express our genes of interest, and we use these to successfully generate new in vivo models of hormone-dependent cancer: these models being important for pre-clinical drug development.